Sandra Horning Buys OLMA Shares
Sandra Horning purchased 29,500 shares of OLMA on June 18, 2026.
Key Points
- Sandra Horning bought 29,500 shares of OLMA on June 18, 2026, alongside other insiders like Graham Walmsley and Yi Larson.
- Shares of OLMA traded near $10.00 on Wednesday, with significant institutional activity including FMR LLC doubling its holdings.
- Analysts maintain a positive outlook, with Guggenheim and Jefferies setting price targets of $35 and $40, respectively.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Sandra Horning made a notable move by purchasing 29,500 shares of OLMA on June 18, 2026. This insider transaction was part of a series of buys by several insiders on the same day.
Insider Buying and Selling at Olema Pharmaceuticals, Inc.
On June 18, 2026, several insiders, including Sandra Horning, Graham Walmsley, Yi Larson, Andrew Rappaport, Gorjan Hrustanovic, and Ian Clark, each bought 29,500 shares of OLMA. These transactions were not made under any pre-planned trading program.
Other Institutional Activity in OLMA
FMR LLC significantly increased its stake in OLMA, adding 5,363,753 shares to hold a total of 10,386,845 shares valued at approximately $154.9 million, reflecting a 106.8% increase. Paradigm Biocapital Advisors LP also grew its holdings by 476,404 shares, resulting in 8,020,576 shares worth about $119.6 million, a 6.3% increase. Bain Capital Life Sciences Investors, LLC, however, reduced its position by 1,035,403 shares, ending with 7,473,238 shares valued at $111.4 million, marking a 12.2% decrease. Janus Henderson Group PLC added 398,294 shares, while BlackRock, Inc. increased its holdings slightly by 88,875 shares.
Olema Pharmaceuticals, Inc. Stock Down 2.6%
Shares of OLMA traded near $10.00 on Wednesday. The stock has seen significant interest from institutional investors, as reflected in recent trading activities. OLMA's market performance is underpinned by these institutional moves and insider buys, indicating a closely watched stock.
$OLMA stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analysts have been bullish on OLMA. On May 13, 2026, Guggenheim maintained its "buy" rating with a $35 price target. Earlier, Jefferies assumed coverage with a "buy" rating and a $40 target on March 19, 2026. JP Morgan also maintained a "buy" rating with a $58 target on March 18, 2026. Overall, the analyst consensus remains positive, with a buy recommendation and several price targets reflecting optimism about OLMA's future performance.
Bottom Line
Sandra Horning's purchase of OLMA shares on June 18, 2026, highlights ongoing insider confidence in the company's prospects. With significant institutional interest and positive analyst ratings, OLMA remains a stock to watch. As always, remember that this information reflects past transactions and may not indicate current positions.
Get Olema Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $OLMA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.